Tech Critiques and Pharmaceutical Market Movements

This chapter features a critique of Apple's innovation stagnation since the iPhone's debut, countered by a defense of its recent product successes. It also examines Johnson & Johnson's significant acquisition of Intercellular Therapies, as well as Moderna's declining stock due to a revised sales outlook for COVID vaccines.